Physician profile
Alan H Cohen
NPI 1902843659
$3,236.75
in general payments reported to CMS, 2019-2025
32 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $227 · 2021: $1,039 · 2022: $821 · 2023: $259 · 2024: $104 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $722.40 | 2021-2025 | Botox, Qulipta |
| Acadia Pharmaceuticals INC | $313.19 | 2019-2025 | Nuplazid |
| Amgen INC. | $170.83 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $151.87 | 2019-2022 | |
| Biogen, INC. | $143.91 | 2019-2021 | |
| Mdd US Operations, LLC | $143.66 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $134.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $127.12 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $126.75 | 2021-2024 | Ingrezza, Ongentys |
| Genentech USA, INC. | $123.82 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $120.51 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $112.38 | 2020-2021 | |
| Allergan, INC. | $98.59 | 2019-2021 | |
| Celgene Corporation | $80.81 | 2023-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $70.99 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $57.93 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $55.41 | 2025 | Crexont |
| Kyowa Kirin, INC. | $48.99 | 2019-2022 | |
| Lilly USA, LLC | $45.84 | 2019-2020 | |
| Eisai INC. | $44.55 | 2020 | |
| Avanir Pharmaceuticals, INC. | $44.05 | 2021-2022 | |
| Abbott Laboratories | $39.31 | 2022 | |
| Sunovion Pharmaceuticals INC. | $38.97 | 2021-2022 | |
| Argenx US, INC. | $31.00 | 2024 | Vyvgart |
| Genzyme Corporation | $29.76 | 2022 | |
| Tg Therapeutics, INC. | $27.94 | 2024 | |
| Springworks Therapeutics, INC. | $27.44 | 2025 | Gomekli |
| Sk Life Science, INC. | $24.36 | 2021 | |
| Ucb, INC. | $22.02 | 2022 | |
| Irhythm Technologies, INC. | $19.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.82 | 2019 | |
| Boston Scientific Corporation | $17.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.